Safety, efficacy, and pharmacokinetics of gremubamab (MEDI3902), an anti-Pseudomonas aeruginosa bispecific human monoclonal antibody, in P. aeruginosa-colonised, mechanically ventilated intensive care unit patients: a randomised controlled trial

BACKGROUND: Ventilator-associated pneumonia caused by Pseudomonas aeruginosa (PA) in hospitalised patients is associated with high mortality. The effectiveness of the bivalent, bispecific mAb MEDI3902 (gremubamab) in preventing PA nosocomial pneumonia was assessed in PA-colonised mechanically ventil...

Descripción completa

Detalles Bibliográficos
Autores principales: Chastre, Jean, François, Bruno, Bourgeois, Marc, Komnos, Apostolos, Ferrer, Ricard, Rahav, Galia, De Schryver, Nicolas, Lepape, Alain, Koksal, Iftihar, Luyt, Charles-Edouard, Sánchez-García, Miguel, Torres, Antoni, Eggimann, Philippe, Koulenti, Despoina, Holland, Thomas L., Ali, Omar, Shoemaker, Kathryn, Ren, Pin, Sauser, Julien, Ruzin, Alexey, Tabor, David E., Akhgar, Ahmad, Wu, Yuling, Jiang, Yu, DiGiandomenico, Antonio, Colbert, Susan, Vandamme, Drieke, Coenjaerts, Frank, Malhotra-Kumar, Surbhi, Timbermont, Leen, Oliver, Antonio, Barraud, Olivier, Bellamy, Terramika, Bonten, Marc, Goossens, Herman, Reisner, Colin, Esser, Mark T., Jafri, Hasan S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9666938/
https://www.ncbi.nlm.nih.gov/pubmed/36380312
http://dx.doi.org/10.1186/s13054-022-04204-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9666938/
https://www.ncbi.nlm.nih.gov/pubmed/36380312
http://dx.doi.org/10.1186/s13054-022-04204-9

Ejemplares similares